EFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARISON OF CANDOR AND MMY1001

• X. Leleu,
• M. Beksac,
• T. Chou,
• M.A. Dimopoulos,
• S. Yoon,
• H.M. Prince,
• A. Chari,
• A. Oriol,
• D.S.D. Siegel,
• M. Khurana,
• M. Qi,
• M. Obreja,
• L. Pour,
• T. Shelekhova

Affiliations

X. Leleu

Chu and Inserm 1402 CIC, Poitiers, France

M. Beksac

Ankara University, Ankara, Turkey

T. Chou

Niigata Cancer Center Hpt, Niigata, Japan

M.A. Dimopoulos

Hematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece

S. Yoon

Seoul National University, Seoul, South Korea

H.M. Prince

Peter MacCallum Cancer Institute, East Melbourne, Australia

A. Chari

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, United States

A. Oriol

Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Barcelona, Spain

D.S.D. Siegel

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, United States

M. Khurana

Amgen Inc., Thousand Oaks, United States

M. Qi

Janssen Research & Development, LLC, Spring House, United States

M. Obreja

Amgen Inc., Thousand Oaks, United States

L. Pour

University Hospital Brno, Brno, Czech Republic

T. Shelekhova

Clinic of Professional Pathology, Saratov, Russian Federation